A Phase 2 interventional study of OPC-34712 and Placebo in Major Depressive Disorder, sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc.. Completed at 50 sites in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2016-02-29.
Sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc. (part of Otsuka Holdings Co., Ltd.) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 24 studies testing brexpiprazole in Depressive Disorder, Major — 1 open to participants now, 1 under way, none of them phase 3. brexpiprazole · Depressive Disorder, Major.
Among the 24 studies testing brexpiprazole in Depressive Disorder, Major, this one is the 6th largest by enrollment, is one of 2 that started in 2009, is one of 3 in phase 2, and was the 1st registered.
3,050 studies on the registry are indexed under Depressive Disorder, Major; 594 are open to participants now.
Browse Depressive Disorder, Major studies →1 of the 24 studies testing brexpiprazole in Depressive Disorder, Major is open now, in 1 country. Recruiting first, the newest first:
Nova Scotia Health Authority · Sites in Canada
Ages 18–65 · Healthy volunteers
By country, each count listing its studies:
brexpiprazole: first FDA approval 2015 (REXULTI), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →
Of the 417 Depressive Disorder, Major studies recruiting now, 93 (22%) set no upper age limit and 297 (71%) stop at 75 or younger; 55 take children under 18; 100 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
24 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 4 · Phase 3 17 · Phase 4 3
First in 2009; this study’s year is marked. 2 started in 2009.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 850 is above the median of 79 across 2,535 interventional studies indexed under Depressive Disorder, Major.
Median enrollment 189 across the 24 interventional studies. Of the 21 that completed or were terminated, 19 (90%) have results posted.
This tab as a report to print or save as PDF → With an account.
22 of 24 have an industry lead sponsor. The 6 most frequent:
This study is registered under Otsuka Pharmaceutical Development & Commercialization, Inc., one of the names counted as Otsuka Holdings Co., Ltd.. Under that name alone:
Otsuka Pharmaceutical Development & Commercialization, Inc. is the lead sponsor of 297 studies on the registry; 19 are open to participants now.
Of its 106 completed or terminated interventional studies of FDA-regulated products, 71 (67%) have results posted.
45 studies in Depressive Disorder, Major by Otsuka Holdings Co., Ltd.: none open now, none under way, none of them phase 3. Of 42 finished, 29 (69%) have results posted.
Among the 45 studies in Depressive Disorder, Major by Otsuka Holdings Co., Ltd., this one is the 10th largest by enrollment of the 40 interventional ones that give a count, is one of 6 that started in 2009, is one of 7 in phase 2, and was the 5th registered.
Otsuka Holdings Co., Ltd.’s Depressive Disorder, Major studies by the year they started, since 2004.
None of the studies under way reaches primary completion within a year.
Among the 24 studies testing brexpiprazole in Depressive Disorder, Major, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Otsuka Holdings Co., Ltd.’s 45 in Depressive Disorder, Major:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Primary: To compare the efficacy of OPC-34712 to placebo as adjunctive treatment to an assigned open-label marketed antidepressant treatment (ADT)in patients who demonstrate an incomplete response to a prospective eight week trial of the same assigned open-label marketed ADT.
A comparison of the Fixed dose arm (OPC-31712, 0.15 mg) verses placebo was included as a general secondary efficacy variable and results for this dose group comparison are included under each of the Outcome Measures.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Subjects with a current Axis I () diagnosis of:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
OPC-34712 + ADT
Drug: OPC-34712 · Drug: ADT
Placebo + ADT
Drug: Placebo · Drug: ADT
Tablets, Oral, 1 - 4 mg OPC-34712 variable dose once daily, 14 weeks
Also known as: Generic Name: Brexpiprazole
Tablets, Oral, 1- 4 mg OPC-34712 once daily, 14 weeks
Tablets, 10 - 225 mgs, dose once daily, 14 weeks
Also known as: Each individual will receive one of the following 6 ADTs:, Escitalopram (Lexapro), Fluoxetine (Prozac), Paroxetine CR (Paxil CR), Sertraline (Zoloft), Desvenlafaxine (Pristiq), Venalfaxine XR (Effexor XR)
Change From the End of Phase A (Week 8 Visit) to the End of Phase B (Week 14 Visit) in Montgomery Asberg Depression Rating Scale (MADRS) Total Score.
The MADRS is utilized as the primary efficacy assessment of a participant's level of depression. The MADRS consists of 10 items, all rated on a 0 to 6 scale with 0 being the "best" rating and 6 being the "worst" rating. The MADRS Total Score is the sum of ratings for all 10 items. The possible Total scores are from 0 to 60. The MADRS Total Score was unevaluable if less than 8 of the 10 items are recorded. If 8 or 9 of the 10 items were recorded, the MADRS Total Score was the mean of the recorded items multiplied by 10 and then rounded to the first decimal place.
Time frame: Week 8 to Week 14
Change From End of Phase A (Week 8 Visit) to End of Phase B (Week 14 Visit) in Mean Clinical Global Impression - Severity of Illness Scale (CGI-S) Score.
CGI-S items are: 0 = not assessed, 1 = normal, not at all ill, 2 = borderline mentally ill, 3 = mildly ill, 4 = moderately ill, 5 = markedly ill, 6 = severely ill, 7 = among the most extremely ill patients. The score 0 (= not assessed) was set to missing. The CGI-S was therefore a 7-point scale from 1 through 7. CGI-S was assessed at screening, baseline and each subsequent visit from Week 1 through Week 14.
Time frame: Week 8 to Week 14
Change From End of Phase A (Week 8 Visit) to End of Phase B (Week 14 Visit) in Mean Quality of Life, Enjoyment, and Satisfaction Questionnaire - Short Form (QLES-Q-SF) Subscale Score - the Overall General Subscore (Sum of First 14 Items).
The Q-LES-Q is a self-report measure to enable physicians to obtain sensitive measures of the degree of enjoyment and satisfaction experienced by participants in various areas of daily functioning. Each item is scored on a five-point scale, with 1= Very Poor; 2=Poor; 3=Fair; 4=Good; 5=Very Good. Lower scores indicating less enjoyment or satisfaction with the activity. The Overall-General Subscore will be defined by summing the scores on all 14 items and expressing it as the percent of the maximum possible score. When expressing the total score as a percentage, if items are left blank the range will be modified to reflect the number of items scored. Raw score is sum of non-missing ratings from items 1 to 14. Minimum score is number of non-missing items. Maximum score is 5\*(minimum score). Range is maximum score minus minimum score. Total score is 100\*(Raw score minus minimum score)/ Range, rounded to nearest integer.
Time frame: Week 8 to Week 14
Change From End of Phase A (Week 8 Visit) to End of Phase B (Week 14 Visit) in Sheehan Disability Scale (SDS) Mean Score (the Mean of 3 Individual Item Scores).
The Sheehan Disability Scale (SDS) is a self-rated instrument used to measure the effect of the participant's symptoms on work/school, social life, and family/home responsibilities. For each of the three items, scores range from 0 through 10. The number most representative of how much each area was disrupted by symptoms is marked along the line from 0 = not at all, to 10 = extremely. For the work/school item, no response was to be entered if the participant did not work or go to school for reasons unrelated to the disorder and a response therefore not being applicable. The Mean SDS Score will be calculated over the three item scores. All three item scores need to be available with the exception of the work/school item score when this item is not applicable.
Time frame: Week 8 to Week 14
Change From End of Phase A (Week 8 Visit) in MADRS Total Score for Every Study Week Visit in Phase B Other Than the Week 14 Visit.
The MADRS is utilized as the primary efficacy assessment of a patient's level of depression. The MADRS consists of 10 items, all rated on a 0 to 6 scale with 0 being the "best" rating and 6 being the "worst" rating. The MADRS Total Score is the sum of ratings for all 10 items. The possible Total scores are from 0 to 60. The MADRS Total Score was unevaluable if less than 8 of the 10 items are recorded. If 8 or 9 of the 10 items were recorded, the MADRS Total Score was the mean of the recorded items multiplied by 10 and then rounded to the first decimal place.
Time frame: Week 8 to each of Week 9, 10, 11, 12 and 13.
Change From End of Phase A (Week 8 Visit) in Mean CGI-S Score for Every Study Week Visit in Phase B Other Than the Week 14 Visit.
CGI-S items are: 0 = not assessed, 1 = normal, not at all ill, 2 = borderline mentally ill, 3 = mildly ill, 4 = moderately ill, 5 = markedly ill, 6 = severely ill, 7 = among the most extremely ill patients. The score 0 (= not assessed) was set to missing. The CGI-S was therefore a 7-point scale from 1 through 7. CGI-S was assessed at screening, baseline and each subsequent visit from Week 1 through Week 14.
Time frame: Week 8 to each of Week 9, 10, 11, 12 and 13.
Change From End of Phase A (Week 8 Visit) to End of Phase B (Week 14 Visit) in Mean Q-LES-Q-SF Item 15 Score (Satisfaction With Medication).
The Q-LES-Q (Short Form) is a self-report measure designed to enable physicians to easily obtain sensitive measures of the degree of enjoyment and satisfaction experienced by participants in various areas of daily functioning. Each item is scored on a five-point scale, with 1= Very Poor; 2=Poor; 3=Fair; 4=Good; 5=Very Good. Lower scores indicating less enjoyment or satisfaction with the activity. According to the scoring system suggested for this questionnaire, item 15 (Satisfaction with Medication) will yield a separate subscore.
Time frame: Week 8 to Week 14
Change From End of Phase A (Week 8 Visit) to End of Phase B (Week 14 Visit) in Mean Q-LES-Q-SF Item 16 Score (Overall Life Satisfaction).
The Q-LES-Q (Short Form) is a self-report measure designed to enable physicians to easily obtain sensitive measures of the degree of enjoyment and satisfaction experienced by participants in various areas of daily functioning. Each item is scored on a five-point scale, with 1= Very Poor; 2=Poor; 3=Fair; 4=Good; 5=Very Good. Lower scores indicating less enjoyment or satisfaction with the activity. According to the scoring system suggested for this questionnaire, item 16 (Overall Life Satisfaction) will yield a separate subscore.
Time frame: Week 8 to Week 14
Change From End of Phase A (Week 8 Visit) for Every Study Week Visit in Phase B in Inventory of Depressive Symptomatology (Self-Report) (IDS-SR) Total Score.
The IDS-SR is a 30-item self-report measure used to assess core diagnostic depressive symptoms as well as atypical and melancholic symptom features of major depressive disorders. The IDS-SR consists of 30 items, all rated on a 0 to 3 scale with 0 being the "best" rating and 3 being the "worst" rating. The IDS-SR Total Score is the sum of ratings of 28 item scores. The possible IDS-SR Total Score ranges from 0 to 84. The IDS-SR Total Score was un-evaluable if less than 23 of the 28 items are recorded. If the number of items was at least 23 and at most 27, the IDS-SR Total Score will be the mean of the recorded items multiplied by 28 and then rounded to the first decimal place.
Time frame: Week 8 to each of Week 9, 10, 11, 12, 13 and 14
Change From End of Phase A (Week 8 Visit) to End of Phase B (Week 14 Visit) in Hamilton Depression Rating Scale (HAM-D17) Score.
The HAM-D17 is utilized as a secondary assessment of a participant's level of depression. The HAM-D (17-Item) consists of 17 items. Eight items are rated on a 0 to 2 scale (items 4, 5, 6, 12, 13, 14, 16 and 17), while nine items (items 1, 2, 3, 7, 8, 9, 10, 11, and 15) are rated on a 0 to 4 scale (twice the weight of the other items). For all of these items, 0 is the "best" rating and the highest score (2 or 4) is the "worst" rating. The possible total scores are from 0 to 52.
Time frame: Week 8 to Week 14
Clinical Global Impression-Improvement Scale (CGI-I) Score at Each Study Week Visit in Phase B.
CGI-I items are: 0 = not assessed, 1 = very much improved, 2 = much improved, 3 = minimally improved, 4 = no change, 5 = minimally worse, 6 = much worse, 7 = very much worse. The score of 0 (= not assessed) will be set to missing. The CGI-I is therefore a 7-point scale from 1 through 7. CGI-I was assessed at each visit in Phase B, and improvement is judged with respect to the participant's condition at baseline. CGI-I was also assessed at each visit in Phase B, but in that phase improvement is judged with respect to the partcipant's condition at the end of Phase A.
Time frame: Week 8 to each of Week 9, 10, 11, 12, 13 and 14.
Percentage of Participants With MADRS Response From End of Phase A (Week 8 Visit).
A MADRS response was defined as \>/= 50% reduction in MADRS Total Score from end of Phase A (Week 8 visit).
Time frame: Week 8 to each of Week 9, 10, 11, 12, 13 and 14.
Percentage of Participants With MADRS Remission From End of Phase A (Week 8 Visit).
A MADRS remission was defined as MADRS Total Score \</= 10 and \>/= 50% reduction in MADRS Total Score from end of Phase A (Week 8 visit).
Time frame: Week 8 to each of Week 9, 10, 11, 12, 13 and 14.
Percentage of Participants With CGI-I Response From End of Phase A (Week 8 Visit).
CGI-I response is defined as CGI-I of 1 \[very much improved\] or 2 \[much improved\].
Time frame: Week 9, 10, 11, 12, 13 and 14.
This study was a Phase 2, multicenter, randomized, double-blind, placebo-controlled study of the safety and efficacy of OPC-34712 as adjunctive therapy in the treatment of participants with major depressive disorder. This study was conducted in the United States at 50 study centers.
| Milestone | OPC-34712 0.15 mg Fixed Dose | OPC-34712 0.5 ± 0.25 mg Low Dose | OPC-34712 1.5 ± 0.5 mg High Dose | Placebo | Participants in Phase A | Participants in Phase A+ |
|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 0 | 849 | 0 |
| Completed | 0 | 0 | 0 | 0 | 664 | 0 |
| Not completed | 0 | 0 | 0 | 0 | 185 | 0 |
| Withdrew: Lost to follow-up | 0 | 0 | 0 | 0 | 33 | 0 |
| Withdrew: Adverse event | 0 | 0 | 0 | 0 | 46 | 0 |
| Withdrew: Met withdrawal criteria | 0 | 0 | 0 | 0 | 4 | 0 |
| Withdrew: Physician decision | 0 | 0 | 0 | 0 | 13 | 0 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 0 | 33 | 0 |
| Withdrew: Protocol deviation | 0 | 0 | 0 | 0 | 56 | 0 |
| Milestone | OPC-34712 0.15 mg Fixed Dose | OPC-34712 0.5 ± 0.25 mg Low Dose | OPC-34712 1.5 ± 0.5 mg High Dose | Placebo | Participants in Phase A | Participants in Phase A+ |
|---|---|---|---|---|---|---|
| Started | 62 | 120 | 121 | 126 | 0 | 0 |
| Completed | 51 | 102 | 100 | 110 | 0 | 0 |
| Not completed | 11 | 18 | 21 | 16 | 0 | 0 |
| Withdrew: Lost to follow-up | 0 | 1 | 3 | 0 | 0 | 0 |
| Withdrew: Adverse event | 2 | 1 | 3 | 1 | 0 | 0 |
| Withdrew: Met withdrawal criteria | 3 | 3 | 6 | 1 | 0 | 0 |
| Withdrew: Physician decision | 1 | 0 | 3 | 1 | 0 | 0 |
| Withdrew: Withdrawal by subject | 1 | 4 | 3 | 3 | 0 | 0 |
| Withdrew: Protocol deviation | 4 | 8 | 2 | 6 | 0 | 0 |
| Withdrew: Lack of efficacy | 0 | 1 | 1 | 4 | 0 | 0 |
| Milestone | OPC-34712 0.15 mg Fixed Dose | OPC-34712 0.5 ± 0.25 mg Low Dose | OPC-34712 1.5 ± 0.5 mg High Dose | Placebo | Participants in Phase A | Participants in Phase A+ |
|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 0 | 0 | 235 |
| Completed | 0 | 0 | 0 | 0 | 0 | 207 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 28 |
| Withdrew: Lost to follow-up | 0 | 0 | 0 | 0 | 0 | 9 |
| Withdrew: Met withdrawal criteria | 0 | 0 | 0 | 0 | 0 | 5 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 0 | 0 | 6 |
| Withdrew: Adverse event | 0 | 0 | 0 | 0 | 0 | 4 |
| Withdrew: Protocol deviation | 0 | 0 | 0 | 0 | 0 | 4 |
The MADRS is utilized as the primary efficacy assessment of a participant's level of depression. The MADRS consists of 10 items, all rated on a 0 to 6 scale with 0 being the "best" rating and 6 being the "worst" rating. The MADRS Total Score is the sum of ratings for all 10 items. The possible Total scores are from 0 to 60. The MADRS Total Score was unevaluable if less than 8 of the 10 items are recorded. If 8 or 9 of the 10 items were recorded, the MADRS Total Score was the mean of the recorded items multiplied by 10 and then rounded to the first decimal place.
| Units on a scale | OPC-34712 0.15 mg Fixed Dose | OPC-34712 0.5 ± 0.25 mg Low Dose | OPC-34712 1.5 ± 0.5 mg High Dose | Placebo |
|---|---|---|---|---|
| Change From the End of Phase A (Week 8 Visit) to the End of Phase B (Week 14 Visit) in Montgomery Asberg Depression Rating Scale (MADRS) Total Score. | -6.62 ± 0.99 | -6.46 ± 0.73 | -8.23 ± 0.74 | -6.09 ± 0.72 |
CGI-S items are: 0 = not assessed, 1 = normal, not at all ill, 2 = borderline mentally ill, 3 = mildly ill, 4 = moderately ill, 5 = markedly ill, 6 = severely ill, 7 = among the most extremely ill patients. The score 0 (= not assessed) was set to missing. The CGI-S was therefore a 7-point scale from 1 through 7. CGI-S was assessed at screening, baseline and each subsequent visit from Week 1 through Week 14.
| Units on a scale | OPC-34712 0.15 mg Fixed Dose | OPC-34712 0.5 ± 0.25 mg Low Dose | OPC-34712 1.5 ± 0.5 mg High Dose | Placebo |
|---|---|---|---|---|
| Change From End of Phase A (Week 8 Visit) to End of Phase B (Week 14 Visit) in Mean Clinical Global Impression - Severity of Illness Scale (CGI-S) Score. | -0.83 ± 0.13 | -0.81 ± 0.10 | -1.06 ± 0.10 | -0.71 ± 0.09 |
The Q-LES-Q is a self-report measure to enable physicians to obtain sensitive measures of the degree of enjoyment and satisfaction experienced by participants in various areas of daily functioning. Each item is scored on a five-point scale, with 1= Very Poor; 2=Poor; 3=Fair; 4=Good; 5=Very Good. Lower scores indicating less enjoyment or satisfaction with the activity. The Overall-General Subscore will be defined by summing the scores on all 14 items and expressing it as the percent of the maximum possible score. When expressing the total score as a percentage, if items are left blank the range will be modified to reflect the number of items scored. Raw score is sum of non-missing ratings from items 1 to 14. Minimum score is number of non-missing items. Maximum score is 5\*(minimum score). Range is maximum score minus minimum score. Total score is 100\*(Raw score minus minimum score)/ Range, rounded to nearest integer.
| Percentage of maximum possible score | OPC-34712 0.15 mg Fixed Dose | OPC-34712 0.5 ± 0.25 mg Low Dose | OPC-34712 1.5 ± 0.5 mg High Dose | Placebo |
|---|---|---|---|---|
| Change From End of Phase A (Week 8 Visit) to End of Phase B (Week 14 Visit) in Mean Quality of Life, Enjoyment, and Satisfaction Questionnaire - Short Form (QLES-Q-SF) Subscale Score - the Overall General Subscore (Sum of First 14 Items). | 7.60 ± 1.82 | 6.53 ± 1.38 | 7.46 ± 1.38 | 5.92 ± 1.34 |
The Sheehan Disability Scale (SDS) is a self-rated instrument used to measure the effect of the participant's symptoms on work/school, social life, and family/home responsibilities. For each of the three items, scores range from 0 through 10. The number most representative of how much each area was disrupted by symptoms is marked along the line from 0 = not at all, to 10 = extremely. For the work/school item, no response was to be entered if the participant did not work or go to school for reasons unrelated to the disorder and a response therefore not being applicable. The Mean SDS Score will be calculated over the three item scores. All three item scores need to be available with the exception of the work/school item score when this item is not applicable.
| Units on a scale | OPC-34712 0.15 mg Fixed Dose | OPC-34712 0.5 ± 0.25 mg Low Dose | OPC-34712 1.5 ± 0.5 mg High Dose | Placebo |
|---|---|---|---|---|
| Change From End of Phase A (Week 8 Visit) to End of Phase B (Week 14 Visit) in Sheehan Disability Scale (SDS) Mean Score (the Mean of 3 Individual Item Scores). | -0.84 ± 0.27 | -0.80 ± 0.21 | -1.27 ± 0.20 | -0.61 ± 0.20 |
The MADRS is utilized as the primary efficacy assessment of a patient's level of depression. The MADRS consists of 10 items, all rated on a 0 to 6 scale with 0 being the "best" rating and 6 being the "worst" rating. The MADRS Total Score is the sum of ratings for all 10 items. The possible Total scores are from 0 to 60. The MADRS Total Score was unevaluable if less than 8 of the 10 items are recorded. If 8 or 9 of the 10 items were recorded, the MADRS Total Score was the mean of the recorded items multiplied by 10 and then rounded to the first decimal place.
| Units on a scale | OPC-34712 0.15 mg Fixed Dose | OPC-34712 0.5 ± 0.25 mg Low Dose | OPC-34712 1.5 ± 0.5 mg High Dose | Placebo |
|---|---|---|---|---|
| Week 9 (N=61,117,116,121) | -2.13 ± 5.22 | -3.00 ± 5.13 | -2.75 ± 5.32 | -2.48 ± 5.43 |
| Week 10 (N=62,119,118,126) | -3.69 ± 5.34 | -3.78 ± 6.27 | -4.97 ± 6.48 | -3.64 ± 6.65 |
| Week 11 (N=62,119,118,126) | -5.53 ± 7.24 | -5.71 ± 7.15 | -5.88 ± 7.09 | -4.40 ± 7.05 |
| Week 12 (N=62,119,118,126) | -6.97 ± 7.65 | -6.31 ± 6.72 | -7.01 ± 7.58 | -4.41 ± 6.74 |
| Week 13 (N=62,119,118,126) | -6.90 ± 7.71 | -6.76 ± 7.20 | -7.18 ± 7.64 | -5.47 ± 7.47 |
CGI-S items are: 0 = not assessed, 1 = normal, not at all ill, 2 = borderline mentally ill, 3 = mildly ill, 4 = moderately ill, 5 = markedly ill, 6 = severely ill, 7 = among the most extremely ill patients. The score 0 (= not assessed) was set to missing. The CGI-S was therefore a 7-point scale from 1 through 7. CGI-S was assessed at screening, baseline and each subsequent visit from Week 1 through Week 14.
| Units on a scale | OPC-34712 0.15 mg Fixed Dose | OPC-34712 0.5 ± 0.25 mg Low Dose | OPC-34712 1.5 ± 0.5 mg High Dose | Placebo |
|---|---|---|---|---|
| Week 9 (N=62,117,116,121) | -0.21 ± 0.60 | -0.26 ± 0.57 | -0.33 ± 0.64 | -0.21 ± 0.58 |
| Week 10 (N=62,119,118,126) | -0.42 ± 0.74 | -0.39 ± 0.77 | -0.61 ± 0.91 | -0.40 ± 0.87 |
| Week 11 (N=62,119,118,126) | -0.53 ± 0.95 | -0.53 ± 0.84 | -0.69 ± 0.92 | -0.47 ± 0.89 |
| Week 12 (N=62,119,118,126) | -0.76 ± 1.02 | -0.66 ± 0.87 | -0.86 ± 1.00 | -0.52 ± 0.98 |
| Week 13 (N=62,119,118,126) | -0.74 ± 1.09 | -0.78 ± 0.95 | -0.88 ± 1.01 | -0.59 ± 1.04 |
The Q-LES-Q (Short Form) is a self-report measure designed to enable physicians to easily obtain sensitive measures of the degree of enjoyment and satisfaction experienced by participants in various areas of daily functioning. Each item is scored on a five-point scale, with 1= Very Poor; 2=Poor; 3=Fair; 4=Good; 5=Very Good. Lower scores indicating less enjoyment or satisfaction with the activity. According to the scoring system suggested for this questionnaire, item 15 (Satisfaction with Medication) will yield a separate subscore.
| Units on a scale | OPC-34712 0.15 mg Fixed Dose | OPC-34712 0.5 ± 0.25 mg Low Dose | OPC-34712 1.5 ± 0.5 mg High Dose | Placebo |
|---|---|---|---|---|
| Change From End of Phase A (Week 8 Visit) to End of Phase B (Week 14 Visit) in Mean Q-LES-Q-SF Item 15 Score (Satisfaction With Medication). | 0.02 ± 0.22 | 0.01 ± 0.25 | 0.02 ± 0.33 | 0.00 ± 0.22 |
The Q-LES-Q (Short Form) is a self-report measure designed to enable physicians to easily obtain sensitive measures of the degree of enjoyment and satisfaction experienced by participants in various areas of daily functioning. Each item is scored on a five-point scale, with 1= Very Poor; 2=Poor; 3=Fair; 4=Good; 5=Very Good. Lower scores indicating less enjoyment or satisfaction with the activity. According to the scoring system suggested for this questionnaire, item 16 (Overall Life Satisfaction) will yield a separate subscore.
| Units on a scale | OPC-34712 0.15 mg Fixed Dose | OPC-34712 0.5 ± 0.25 mg Low Dose | OPC-34712 1.5 ± 0.5 mg High Dose | Placebo |
|---|---|---|---|---|
| Change From End of Phase A (Week 8 Visit) to End of Phase B (Week 14 Visit) in Mean Q-LES-Q-SF Item 16 Score (Overall Life Satisfaction). | 0.30 ± 0.84 | 0.30 ± 0.79 | 0.35 ± 0.93 | 0.28 ± 1.00 |
The IDS-SR is a 30-item self-report measure used to assess core diagnostic depressive symptoms as well as atypical and melancholic symptom features of major depressive disorders. The IDS-SR consists of 30 items, all rated on a 0 to 3 scale with 0 being the "best" rating and 3 being the "worst" rating. The IDS-SR Total Score is the sum of ratings of 28 item scores. The possible IDS-SR Total Score ranges from 0 to 84. The IDS-SR Total Score was un-evaluable if less than 23 of the 28 items are recorded. If the number of items was at least 23 and at most 27, the IDS-SR Total Score will be the mean of the recorded items multiplied by 28 and then rounded to the first decimal place.
| Units on a scale | OPC-34712 0.15 mg Fixed Dose | OPC-34712 0.5 ± 0.25 mg Low Dose | OPC-34712 1.5 ± 0.5 mg High Dose | Placebo |
|---|---|---|---|---|
| Week 9 (N=61, 117,116,121) | -0.98 ± 7.28 | -1.88 ± 6.60 | -2.04 ± 5.93 | -0.98 ± 7.58 |
| Week 10 (N=62, 119, 118, 126) | -2.13 ± 8.02 | -2.58 ± 7.37 | -4.08 ± 7.25 | -1.62 ± 7.76 |
| Week 11 (N=62, 119, 118, 126) | -3.58 ± 7.81 | -3.41 ± 7.88 | -4.82 ± 7.96 | -2.09 ± 8.42 |
| Week 12 (N=62, 119, 118, 126) | -5.11 ± 9.42 | -3.77 ± 8.45 | -5.77 ± 9.26 | -2.07 ± 8.42 |
| Week 13 (N=62, 119, 118, 126) | -5.34 ± 9.15 | -5.22 ± 8.72 | -5.65 ± 8.84 | -2.37 ± 8.45 |
| Week 14 (N=62, 119, 118, 126) | -5.55 ± 9.65 | -4.96 ± 9.37 | -6.74 ± 9.76 | -3.08 ± 9.32 |
The HAM-D17 is utilized as a secondary assessment of a participant's level of depression. The HAM-D (17-Item) consists of 17 items. Eight items are rated on a 0 to 2 scale (items 4, 5, 6, 12, 13, 14, 16 and 17), while nine items (items 1, 2, 3, 7, 8, 9, 10, 11, and 15) are rated on a 0 to 4 scale (twice the weight of the other items). For all of these items, 0 is the "best" rating and the highest score (2 or 4) is the "worst" rating. The possible total scores are from 0 to 52.
| Units on a scale | OPC-34712 0.15 mg Fixed Dose | OPC-34712 0.5 ± 0.25 mg Low Dose | OPC-34712 1.5 ± 0.5 mg High Dose | Placebo |
|---|---|---|---|---|
| Change From End of Phase A (Week 8 Visit) to End of Phase B (Week 14 Visit) in Hamilton Depression Rating Scale (HAM-D17) Score. | -5.77 ± 0.86 | -5.28 ± 0.63 | -6.59 ± 0.62 | -5.23 ± 0.59 |
CGI-I items are: 0 = not assessed, 1 = very much improved, 2 = much improved, 3 = minimally improved, 4 = no change, 5 = minimally worse, 6 = much worse, 7 = very much worse. The score of 0 (= not assessed) will be set to missing. The CGI-I is therefore a 7-point scale from 1 through 7. CGI-I was assessed at each visit in Phase B, and improvement is judged with respect to the participant's condition at baseline. CGI-I was also assessed at each visit in Phase B, but in that phase improvement is judged with respect to the partcipant's condition at the end of Phase A.
| Units on a scale | OPC-34712 0.15 mg Fixed Dose | OPC-34712 0.5 ± 0.25 mg Low Dose | OPC-34712 1.5 ± 0.5 mg High Dose | Placebo |
|---|---|---|---|---|
| Week 9 (N=62, 117, 116, 121) | 3.39 ± 0.86 | 3.30 ± 0.79 | 3.20 ± 0.80 | 3.31 ± 0.79 |
| Week 10 (N=62, 119, 118, 126) | 3.16 ± 0.94 | 3.19 ± 0.90 | 2.95 ± 0.93 | 3.11 ± 1.04 |
| Week 11 (N=62, 119, 118, 126) | 2.94 ± 0.94 | 3.02 ± 0.98 | 2.80 ± 0.92 | 2.94 ± 1.01 |
| Week 12 (N=62, 119, 118, 126) | 2.87 ± 1.06 | 2.90 ± 0.99 | 2.70 ± 1.03 | 2.95 ± 1.06 |
| Week 13 (N=62, 119, 118, 126) | 2.85 ± 1.13 | 2.76 ± 1.02 | 2.64 ± 1.06 | 2.90 ± 1.14 |
| Week 14 (N=62, 119, 118, 126) | 2.74 ± 1.16 | 2.78 ± 1.02 | 2.52 ± 1.08 | 2.83 ± 1.12 |
A MADRS response was defined as \>/= 50% reduction in MADRS Total Score from end of Phase A (Week 8 visit).
| Percentage of participants | OPC-34712 0.15 mg Fixed Dose | OPC-34712 0.5 ± 0.25 mg Low Dose | OPC-34712 1.5 ± 0.5 mg High Dose | Placebo |
|---|---|---|---|---|
| Week 9 (N=61, 117, 116, 121) | 4.92 | 6.84 | 2.59 | 8.26 |
| Week 10 (N=62, 119, 118, 126) | 8.06 | 8.40 | 11.0 | 9.52 |
| Week 11 (N=62, 119, 118, 126) | 19.4 | 15.1 | 18.6 | 13.5 |
| Week 12 (N=62, 119, 118, 126) | 30.6 | 15.1 | 25.4 | 11.9 |
| Week 13 (N=62, 119, 118, 126) | 24.2 | 22.7 | 25.4 | 18.3 |
| Week 14 (N=62, 119, 118, 126) | 27.4 | 20.2 | 34.7 | 19.8 |
A MADRS remission was defined as MADRS Total Score \</= 10 and \>/= 50% reduction in MADRS Total Score from end of Phase A (Week 8 visit).
| Percentage of participants | OPC-34712 0.15 mg Fixed Dose | OPC-34712 0.5 ± 0.25 mg Low Dose | OPC-34712 1.5 ± 0.5 mg High Dose | Placebo |
|---|---|---|---|---|
| Week 9 (N=61, 117, 116, 121) | 3.28 | 1.71 | 1.72 | 4.13 |
| Week 10 (N=62, 119, 118, 126) | 8.06 | 5.04 | 10.2 | 8.73 |
| Week 11 (N=62, 119, 118, 126) | 12.9 | 10.1 | 14.4 | 11.1 |
| Week 12 (N=62, 119, 118, 126) | 21.0 | 10.1 | 19.5 | 10.3 |
| Week 13 (N=62, 119, 118, 126) | 19.4 | 16.8 | 15.3 | 15.1 |
| Week 14 (N=62, 119, 118, 126) | 22.6 | 15.1 | 23.7 | 13.5 |
CGI-I response is defined as CGI-I of 1 \[very much improved\] or 2 \[much improved\].
| percentage of participants | OPC-34712 0.15 mg Fixed Dose | OPC-34712 0.5 ± 0.25 mg Low Dose | OPC-34712 1.5 ± 0.5 mg High Dose | Placebo |
|---|---|---|---|---|
| Week 9 (N=62, 117, 116, 121) | 16.1 | 11.1 | 14.7 | 14.9 |
| Week 10 (N=62, 119, 118, 126) | 25.8 | 17.6 | 24.6 | 27.0 |
| Week 11 (N=62, 119, 118, 126) | 32.3 | 29.4 | 35.6 | 29.4 |
| Week 12 (N=62, 119, 118, 126) | 35.5 | 33.6 | 42.4 | 31.7 |
| Week 13 (N=62, 119, 118, 126) | 37.1 | 37.0 | 49.2 | 33.3 |
| Week 14 (N=62, 119, 118, 126) | 38.7 | 37.0 | 52.5 | 41.3 |
Collected over From Randomization to 30 (+2) days after the end of Phase B (Week 14/End of treatment).. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| OPC-34712 0.15 mg Fixed Dose | — | 0/62 (0%) | 21/62 (33.9%) |
| OPC-34712 0.5 ± 0.25 mg Low Dose | — | 0/120 (0%) | 37/120 (30.8%) |
| OPC-34712 1.5 ± 0.5 mg High Dose | — | 2/121 (1.7%) | 47/121 (38.8%) |
| Placebo | — | 1/126 (0.8%) | 37/126 (29.4%) |
| Event | OPC-34712 0.15 mg Fixed Dose | OPC-34712 0.5 ± 0.25 mg Low Dose | OPC-34712 1.5 ± 0.5 mg High Dose | Placebo |
|---|---|---|---|---|
| Radius fractureInjury, poisoning and procedural complications | 0/62 | 0/120 | 1/121 | 0/126 |
| Ulna fractureInjury, poisoning and procedural complications | 0/62 | 0/120 | 1/121 | 0/126 |
| Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders | 0/62 | 0/120 | 1/121 | 0/126 |
| Renal massRenal and urinary disorders | 0/62 | 0/120 | 0/121 | 1/126 |
| Event | OPC-34712 0.15 mg Fixed Dose | OPC-34712 0.5 ± 0.25 mg Low Dose | OPC-34712 1.5 ± 0.5 mg High Dose | Placebo |
|---|---|---|---|---|
| HeadacheNervous system disorders | 5/62 | 9/120 | 6/121 | 12/126 |
| Upper respiratory tract infectionInfections and infestations | 4/62 | 10/120 | 7/121 | 6/126 |
| DiarrhoeaGastrointestinal disorders | 1/62 | 0/120 | 10/121 | 5/126 |
| AkathisiaNervous system disorders | 4/62 | 6/120 | 10/121 | 4/126 |
| InsomniaPsychiatric disorders | 5/62 | 3/120 | 4/121 | 4/126 |
| Weight increasedInvestigations | 3/62 | 7/120 | 9/121 | 1/126 |
| RestlessnessPsychiatric disorders | 4/62 | 1/120 | 5/121 | 6/126 |
| NauseaGastrointestinal disorders | 0/62 | 7/120 | 2/121 | 3/126 |
| NasopharyngitisInfections and infestations | 3/62 | 7/120 | 5/121 | 2/126 |
| Age, Continuous(Years) | OPC-34712 0.15 mg Fixed Dose | OPC-34712 0.5 ± 0.25 mg Low Dose | OPC-34712 1.5 ± 0.5 mg High Dose | Placebo | Total |
|---|---|---|---|---|---|
| Mean | 43.9 ± 10.8 | 44.0 ± 11.8 | 43.7 ± 11.6 | 43.3 ± 11.5 | 43.7 ± 11.5 |
| Sex: Female, Male(Participants) | OPC-34712 0.15 mg Fixed Dose | OPC-34712 0.5 ± 0.25 mg Low Dose | OPC-34712 1.5 ± 0.5 mg High Dose | Placebo | Total |
|---|---|---|---|---|---|
| Female | 41 | 86 | 80 | 82 | 289 |
| Male | 21 | 34 | 41 | 44 | 140 |
The record gives a start of May 2009, a primary completion of Jun 2010 and a completion of Jul 2010. It does not say whether these dates are actual or estimated.
Results were first posted in Dec 2015, 5 years 6 months after primary completion. A results delay was requested in May 2012.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Brexpiprazole
Otsuka Pharmaceutical Development & Commercialization, Inc. →